Novartis Under Investigation Over MS Drug Marketing
According to a regulatory filing with the U.S. Securities and Exchange Commission, the U.S. Attorney's Office for the Southern District of New York served the company with a civil investigative demand to look into the allegations just this month.
The office requested documents and information regarding Novartis' marketing practices for Gilenya and any payments it...
Already a subscriber? Click here to login